Adaptimmune Therapeutics PLC (NASDAQ:ADAP) released its earnings results on Thursday. The biotechnology company reported $0.00 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.26, Yahoo Finance Previews reports. Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%.

A number of research analysts have recently commented on the company. Leerink Swann restated an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 8th. Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research note on Wednesday, October 4th. ValuEngine upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Sunday, July 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $10.00 price objective on shares of Adaptimmune Therapeutics PLC in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $11.58.

TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/02/adaptimmune-therapeutics-plc-adap-posts-earnings-results.html.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.